StockTipsArenaBeta

BUY Emcure Pharmaceuticals Limited — HDFC Securities

BUYEmcure Pharmaceuticals Limited
Emcure Pharmaceuticals share price target & all analyst calls

byHDFC SecuritiesHorizon: 1 year2 Nov 2026via Moneycontrol Business (broker lists)

Entry₹1,883.5Inferred
Target₹2,208
Total upside +17.23% (call closed)
Stop lossNot given
Exit₹2,2085 Nov 2026, 12:11 pm
Target hit+17.23%0.00%upside left
Follow HDFC Securities for new calls(100% target hit, 12 closed calls)Get alertsWatch EMCURE for new buy/sell callsGet alertsSee 4 active Long-term calls on EMCURESee 273 active Long-term picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 5 Nov 2026
19 supporting6 neutral2 opposing
Supports the BUY call (19)

Emcure Pharmaceuticals Q2FY27 Results: Standalone PAT up 111% YoY

NewsGoogle News·5 Nov · today

(opens in new tab)

4 other SEBI-registered advisors have active long-term BUY calls on this stock, with 3 issued in the last 14 days

Advisor consensus · same horizon·5 Nov · today

Emcure Pharma shares hit 10% upper circuit as Q2 net profit rises

NewsHbl·4 Nov · yesterday

(opens in new tab)

Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike; Jefferies raises target price by 8%

NewsEt-Markets·4 Nov · yesterday

(opens in new tab)

Emcure Pharma shares at record high! Stock soars 10% today, up 16% in 2 days: More rally ahead? Buy, sell or hold?

NewsLivemint·4 Nov · yesterday

(opens in new tab)
Neutral / worth noting (6)

For approval of Unaudited Financial Results (Standalone and Consolidated) for the quarter and half-year ended September 30, 2026.

BSE · Board Meeting·3 Nov · yesterday

(opens in new tab)

Emcure Pharmaceuticals has proposed a scheme of amalgamation for its wholly owned subsidiaries, Zuventus Healthcare Limited and Emcutix Biopharmaceuticals Limited, into the parent company.

BSE · Company Update·12 Oct · 3w ago

(opens in new tab)
Weighs against the BUY call (2)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Emcure Pharmaceuticals

All analyst calls on Emcure Pharmaceuticals

More from HDFC Securities

Every call and its outcome